Asia Pacific Rapid Diagnostics will grow by 10.9% annually with a total addressable market cap of $ 129,373.7 million over 2022-2031, driven by the growing demand for POC diagnostics, the rising prevalence of chronic diseases coupled with the increasing aging population, the growing necessity for rapid decision making in emergency departments, increase in awareness regarding early diagnosis of disease, and emerging technological innovations.
Highlighted with 35 tables and 64 figures, this 126-page report “Asia Pacific Rapid Diagnostics Market 2021-2031 by Product (Consumables, Analyzers/Instruments), Prescription (Professional, OTC), Platform (Immunoassays, Molecular Detection, Others), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Asia Pacific Rapid Diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific Rapid Diagnostics market in every aspect of the classification from perspectives of Product, Prescription, Platform, Application, End User, and Country.
Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Consumables
• Analyzers/Instruments
Based on Prescription, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Professional Diagnostics
• OTC Based Testing
By Platform, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Immunoassays
o Lateral Flow Assays
o Serological Assays
o Other Immunoassays
• Molecular Detection
o Polymerase Chain Reaction (PCR)
o Other Molecular Detection Tests
• Other Platforms
By Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Blood Glucose Testing
• Cardiometabolic Testing
• Infectious Disease Testing
o COVID-19 Testing
o Healthcare-associated Infections (HAI) Testing
o Hepatitis Testing
o Tropical Diseases Testing
o HIV Testing
o Influenza Testing
o Sexually Transmitted Diseases (STD) Testing
o Other Infectious Diseases Testing
• Blood Coagulation Testing
• Hematology Testing
• Cancer Testing
• Drug Abuse Testing
• Pregnancy & Fertility Testing
• Other Applications
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Hospitals & Clinics
• Laboratories
• Individuals/Homecare
• Other End Users
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product, Prescription and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Diagnostics
ACON Laboratories
Becton Dickinson and Co.
BioMérieux S.A.
Bio-Rad Laboratories, Inc.
Chembio Diagnostic Systems
Danaher Corp.
F. Hoffmann La Roche Ltd.
GlySens Inc.
Meridian Bioscience Inc.
OraSure Technologies Inc.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Trinity Biotech Plc
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter’s Fiver Forces Analysis 39
3 Segmentation of Asia Pacific Market by Product 43
3.1 Market Overview by Product 43
3.2 Consumables 45
3.3 Analyzers/Instruments 46
4 Segmentation of Asia Pacific Market by Prescription 47
4.1 Market Overview by Prescription 47
4.2 Professional Diagnostics 49
4.3 OTC Based Testing 50
5 Segmentation of Asia Pacific Market by Platform 51
5.1 Market Overview by Platform 51
5.2 Immunoassays 53
5.2.1 Lateral Flow Assays 55
5.2.2 Serological Assays 56
5.2.3 Other Immunoassays 57
5.3 Molecular Detection 58
5.3.1 Polymerase Chain Reaction (PCR) 59
5.3.2 Other Molecular Detection Tests 60
5.4 Other Platforms 61
6 Segmentation of Asia Pacific Market by Application 62
6.1 Market Overview by Application 62
6.2 Blood Glucose Testing 64
6.3 Cardiometabolic Testing 65
6.4 Infectious Disease Testing 66
6.4.1 COVID-19 Testing 68
6.4.2 Healthcare-associated Infections (HAI) Testing 69
6.4.3 Hepatitis Testing 70
6.4.4 Tropical Diseases Testing 71
6.4.5 HIV Testing 72
6.4.6 Influenza Testing 73
6.4.7 Sexually Transmitted Diseases (STD) Testing 74
6.4.8 Other Infectious Diseases Testing 75
6.5 Blood Coagulation Testing 76
6.6 Hematology Testing 77
6.7 Cancer Testing 78
6.8 Drug Abuse Testing 79
6.9 Pregnancy & Fertility Testing 80
6.10 Other Applications 81
7 Segmentation of Asia Pacific Market by End User 82
7.1 Market Overview by End User 82
7.2 Hospitals & Clinics 84
7.3 Laboratories 85
7.4 Individuals/Homecare 86
7.5 Other End Users 87
8 Asia-Pacific Market 2021-2031 by Country 88
8.1 Overview of Asia-Pacific Market 88
8.2 Japan 91
8.3 China 94
8.4 Australia 96
8.5 India 98
8.6 South Korea 100
8.7 Rest of APAC Region 102
9 Competitive Landscape 104
9.1 Overview of Key Vendors 104
9.2 New Product Launch, Partnership, Investment, and M&A 109
9.3 Company Profiles 111
Abbott Diagnostics 111
ACON Laboratories 113
Becton Dickinson and Co. 114
BioMérieux S.A. 115
Bio-Rad Laboratories, Inc. 116
Chembio Diagnostic Systems 117
Danaher Corp. 118
F. Hoffmann La Roche Ltd. 119
GlySens Inc. 120
Meridian Bioscience Inc. 121
OraSure Technologies Inc. 122
Siemens Healthineers AG 123
Thermo Fisher Scientific Inc. 124
Trinity Biotech Plc 125
RELATED REPORTS 126
List of Tables:
Table 1. Snapshot of Asia Pacific Rapid Diagnostics Market in Balanced Perspective, 2021-2031 17
Table 2. World Economic Outlook, 2021-2031 21
Table 3. World Economic Outlook, 2021-2023 22
Table 4. World Health Spending by Region, $ bn, 2013-2020 31
Table 5. Main Product Trends and Market Opportunities in Asia Pacific Rapid Diagnostics Market 35
Table 6. Asia Pacific Rapid Diagnostics Market by Product, 2021-2031, $ mn 43
Table 7. Asia Pacific Rapid Diagnostics Market by Prescription, 2021-2031, $ mn 47
Table 8. Asia Pacific Rapid Diagnostics Market by Platform, 2021-2031, $ mn 51
Table 9. Asia Pacific Rapid Diagnostics Market: Immunoassays by Type, 2021-2031, $ mn 54
Table 10. Asia Pacific Rapid Diagnostics Market: Molecular Detection by Type, 2021-2031, $ mn 58
Table 11. Asia Pacific Rapid Diagnostics Market by Application, 2021-2031, $ mn 62
Table 12. Asia Pacific Rapid Diagnostics Market: Infectious Disease Testing by Type, 2021-2031, $ mn 67
Table 13. Asia Pacific Rapid Diagnostics Market by End User, 2021-2031, $ mn 82
Table 14. APAC Rapid Diagnostics Market by Country, 2021-2031, $ mn 89
Table 15. Japan Rapid Diagnostics Market by Product, 2021-2031, $ mn 93
Table 16. Japan Rapid Diagnostics Market by Prescription, 2021-2031, $ mn 93
Table 17. Japan Rapid Diagnostics Market by Application, 2021-2031, $ mn 93
Table 18. China Rapid Diagnostics Market by Product, 2021-2031, $ mn 95
Table 19. China Rapid Diagnostics Market by Prescription, 2021-2031, $ mn 95
Table 20. China Rapid Diagnostics Market by Application, 2021-2031, $ mn 95
Table 21. Australia Rapid Diagnostics Market by Product, 2021-2031, $ mn 97
Table 22. Australia Rapid Diagnostics Market by Prescription, 2021-2031, $ mn 97
Table 23. Australia Rapid Diagnostics Market by Application, 2021-2031, $ mn 97
Table 24. India Rapid Diagnostics Market by Product, 2021-2031, $ mn 99
Table 25. India Rapid Diagnostics Market by Prescription, 2021-2031, $ mn 99
Table 26. India Rapid Diagnostics Market by Application, 2021-2031, $ mn 99
Table 27. South Korea Rapid Diagnostics Market by Product, 2021-2031, $ mn 101
Table 28. South Korea Rapid Diagnostics Market by Prescription, 2021-2031, $ mn 101
Table 29. South Korea Rapid Diagnostics Market by Application, 2021-2031, $ mn 101
Table 30. Rapid Diagnostics Market in Rest of APAC by Country/Region, 2021-2031, $ mn 103
Table 31. Rapid Diagnostic Analyzers by Vendor 106
Table 32. Recent Product Launches, 2018-2021 110
Table 33. Abbott Diagnostics: Company Snapshot 111
Table 34. Abbott Diagnostics: Business Segmentation 112
Table 35. Abbott Diagnostics: Product Portfolio 112
